Ricerc@Sapienza

Malassezia species are natural inhabitants of the healthy skin. However, under certain
conditions, they may cause or exacerbate several skin diseases. The ability of this fungus
to colonize or infect is determined by complex interactions between the fungal cell and
its virulence factors. This study aims to evaluate “in vitro” the hydrophobicity levels,
the adherence on a plastic surface and the biofilm formation of 16 clinical isolates of
Malassezia furfur. Cellular surface hydrophobicity (CSH) levels were determined by twophase

The genus Malassezia comprises a heterogeneous group of species that cause similar pathologies. Malassezia yeasts were considered as the most abundant skin eukaryotes of the total skin mycobiome. The ability of this fungus to colonize or infect is determined by complex interactions between the fungal cell and its virulence factors. This study aims to evaluate in vitro the hydrophobicity levels, the adherence capacity on a polystyrene surface and the ability to form biofilm of 19 isolates, including M. sympodialis, M. globosa, and M.

Introduction. Epilepsy is a common neurological disease requiring complex therapies, which have been unable to achieve seizure control in 30% of patients. Poor adherence has been recognized as a possible determinant of drug-resistance. Prolonged-release formulations of anti-epileptic drugs might help increase adherence, minimize side effects and pharmacological interactions. Areas Covered. Pregabalin (PGB) has peculiar pharmacodynamics and almost ideal pharmacokinetics, except for a short half-life and therefore requiring multiple daily dosing.

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy.